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EVIDENCE-BASED ANSWER
A
 Which oral antibiotics 
are best for acne?
 doxycycline is effective
 (strength of recommendation 
[SOR]: B, randomized controlled trial) and 
the antibiotic of choice (SOR: C, expert 
opinion) for moderate to severe infl amma-
tory acne requiring oral treatment. Limit-
ing side eff ects include photosensitivity 
and gastrointestinal (GI) disturbance. 
Other members of the tetracycline 
family are considered second-line agents 
because of their side-eff ect profi le and 
are contraindicated in pregnancy and for 
children younger than 12 years (SOR: A, 
meta-analysis, and C, expert opin-
ion). For these patients, erythromy-
cin is eff ective and better studied than 
azithromycin (SOR: C, expert opinion). 
Otherwise, emerging resistance and GI dis-
turbances make erythromycin a third-line 
treatment. 
Th e use of oral antibiotics should be 
limited to moderate to severe infl ammato-
ry acne unresponsive to topical therapies, 
including retinoids and antibiotics (SOR: 
C, expert opinion). Oral antibiotics should 
be used for at least 6 to 8 weeks and dis-
continued after 12 to 18 weeks of therapy 
(SOR: C, expert opinion).
Evidence summary
Acne vulgaris is an extremely common disor-
der aff ecting up to 95% of adolescents.1 Doxy-
cycline improves infl ammatory lesions and 
has a tolerable side-eff ect profi le. 
Doxycycline: 
Fewer lesions, few side effects
A 2003 randomized, double-blind, controlled 
trial of 51 patients demonstrated that a sub-
antimicrobial dose of doxycycline (20 mg oral-
ly twice a day) reduced comedonal lesions by 
53.2% (from 31 to 16; P=.04) and infl ammatory 
lesions by 50.1% (from 55 to 25; P<.01), where-
as placebo decreased comedonal lesions by 
10.6% (from 51 to 46; P=.4) and infl ammatory 
lesions by 30.2% (from 27 to 19; P<.01).2
Th e most commonly reported adverse 
eff ects of doxycycline are GI disturbance and 
sensitivity to ultraviolet radiation (sunlight). 
A recent systematic review found an adverse 
event rate of 13 per 1 million prescriptions 
written.3
Minocycline: Probably effective, 
but not the fi rst choice
A 2003 Cochrane review examined 27 ran-
domized trials that compared oral minocy-
cline with placebo or other active treatments, 
including topical and systemic antibiotics, 
in a total of 3031 patients with acne vulgaris 
on the face or upper trunk.4 Th e review de-
termined that minocycline is probably an ef-
fective treatment for moderate acne vulgaris. 
However, no reliable evidence from random-
ized controlled trials (RCTs) justifi es its use as 
a fi rst-line agent, especially given its higher 
cost relative to other treatments.
Drug resistance weakens
macrolides’ “punch” 
Macrolide antibiotics, primarily erythromy-
cin, were at one time considered fi rst-line 
treatment for acne, but have fallen out of 
favor because of emerging drug resistance. 
Nevertheless, erythromycin’s price and safety 
in pregnant women and young children has 
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maintained its standing in acne therapy. A 
1986 RCT that compared erythromycin with 
tetracycline found comparable effi  cacy: a 
65% reduction in papules, from 21 to 12 le-
sions, for erythromycin and a 62% reduc-
tion, from 17 to 10 lesions, for tetracycline 
(P<.0001).5 Th e main side eff ect of macrolide 
antibiotics is GI disturbance.
A 2006 RCT randomized 290 patients to 
the macrolide azithromycin (500 mg daily for 
3 consecutive days a week in the fi rst month, 
then 250 mg every other day for 2 months) 
or tetracycline (1 g daily for 1 month, then 
500 mg daily for 2 months). Th e drugs pro-
duced comparable results: an 84.7% im-
provement with azithromycin and a 79.7% 
improvement with tetracycline (P<.05).6 
Compared with other macrolides and tetra-
cycline , azithromycin has a more tolerable 
side- eff ect profi le with fewer GI disturbances. 
Lack of suffi  cient data on trimethoprim 
± sulfamethoxazole, fl uoroquinolones, and 
TABLE 1 
Estimated cost of oral acne medications
Medication
Dose, formulation, 
and frequency Cost of 30-day supply*
Doxycycline hyclate 100 mg capsule daily $12.99
Doxycycline hyclate 100 mg tablet daily $20.99
Extended-release minocycline 45 mg tablet daily $450.97
Minocycline 100 mg capsule twice a day $45.98
Minocycline 100 mg tablet twice a day $227.98
Erythromycin base 250 mg enteric-coated capsule 
4 times a day
$154.62
Erythromycin base 250 mg tablet 4 times a day $114.62
Azithromycin 500 mg tablet daily, 
3 days/wk
$175.20
*http://www.drugstore.com. Accessed April 10, 2011. 
TABLE 2 
Safety and adverse-eff ect profi les of acne medications8
Medication Adverse effects Pregnancy 
category
Lactation 
safety
Appropriate age 
range
Doxycycline 
hyclate
Photosensitivity, GI 
disturbance, elevated BUN
D Avoid >12 y 
Minocycline Tooth discoloration, 
dizziness, hypersensitivity 
syndrome
D Avoid; 
milk effects 
possible
>12 y
Erythromycin 
base
GI disturbance, nausea B Safe FDA-approved 
for children
Azithromycin Abdominal pain, 
GI disturbance
B Minimal risk Extended-release 
formula not 
FDA-approved 
for children
BUN, blood urea nitrogen; GI, gastrointestinal.
Doxycycline is 
the antibiotic 
of choice for 
moderate 
to severe 
infl ammatory 
acne requiring 
oral treatment. 
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cephalosporins precludes their inclusion in 
routine acne treatment.
Recommendations 
Th e American Academy of Pediatrics (AAP) 
recommends topical retinoids as the founda-
tion of treatment for most acne patients, and a 
topical microbial agent for additional therapy. 
Oral antibiotics should be reserved for moder-
ate to severe infl ammatory acne; tetracyclines 
are the standard fi rst-line choice in most cas-
es. Th e AAP warns against giving tetracyclines 
to children younger than 10 years because of 
the risk of permanent discoloration of teeth 
and abnormal skeletal development.7,8
Th e American Academy of Dermatology 
also recommends topical retinoids as fi rst-
line therapy for acne followed by oral doxycy-
cline or minocycline if needed. Erythromycin 
is recommended for patients who can’t use 
tetracyclines, but with a warning about pos-
sible bacterial resistance.9
TABLE 1 shows the cost of various acne 
medications. TABLE 2 outlines their safety and 
risk profi les.                  JFP
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